A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study

World J Urol. 2023 Apr;41(4):1077-1083. doi: 10.1007/s00345-023-04316-z. Epub 2023 Feb 15.

Abstract

Purpose: To show the effect of a 6-month (4 times weekly followed by 5 times monthly) maintenance mitomycin C regimen on the prevention of intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).

Methods: A total of 119 patients undergoing a RNU between 2007 and 2021 in a single center hospital were retrospectively reviewed. A total of 66 patients were eligible for further analysis. 27 patients received no post-operative MMC (median follow-up: 110 months) and 39 patients received a 6-month (4 times weekly, 5 times monthly) maintenance regimen of MMC (median follow up: 48 months). The primary outcome was the 1-, 2- and 5-year bladder recurrence free survival (BRFS).

Results: There was a significant difference (p = 0.001) in BRFS between the two groups. The 1-, 2, and 5-year BRFS for the MMC- group was 67%, 63% and 43%, respectively. The 1-, 2- and 5-year BRFS for the MMC + group was 95%, 86% and 86%, respectively. Univariate analysis showed no other potential prognostic factors that had a significant effect on the BRFS.

Conclusion: A 6-month maintenance schedule of MMC is effective at significantly reducing the risk of IVR after RNU for UTUC. We could not find any other significant prognostic factors to predict IVR.

Keywords: Intravesical chemotherapy; Intravesical recurrence; Mitomycin C; Radical nephroureterectomy; Upper tract urothelial carcinoma.

MeSH terms

  • Carcinoma, Transitional Cell* / pathology
  • Carcinoma, Transitional Cell* / surgery
  • Humans
  • Mitomycin / therapeutic use
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / prevention & control
  • Nephroureterectomy
  • Retrospective Studies
  • Ureteral Neoplasms* / pathology
  • Ureteral Neoplasms* / surgery
  • Urinary Bladder Neoplasms* / pathology
  • Urinary Bladder Neoplasms* / surgery

Substances

  • Mitomycin